MAPT and Alzheimer disease: The primary aim of this paper was to determine the prognostic utility of [18F]GTP1, a second-generation tau PET tracer that has been and is being used in multiple completed and ongoing therapeutic trials in AD, for identifying individuals at risk for more rapid clinical progression.